InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...

To help protect yourself and your family from getting seriously ill, you may want to learn about additional vaccine options ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

Risk factors for relapse after reinduction treatment with rituximab in patients with antineutrophil cytoplasmic ...

Oral micronutrient supplementation showed no benefit on geographic atrophy lesion growth among a patient group from the OAKS and DERBY trials, according to a speaker ...

Negative symptoms of schizophrenia affect motivation, emotion, and daily life. Learn the signs, why they’re often missed, and ...

Nektar Therapeutics is advancing Rezpeg in atopic dermatitis and alopecia areata. Click here for key insights on NKTR's ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of ...

On December 24, President Ilham Aliyev and First Lady Mehriban Aliyeva visited several liberated areas, a visit that carried ...

In a subgroup analysis of patients with polypoidal choroidal vasculopathy, aflibercept 8 mg achieved similar vision gains to ...

The co-founder of SCIMaP looks at the year of NIH cuts — and what they say about the future of American research.

Maintenance therapy with subcutaneous infliximab was more effective than placebo regardless of disease location or segment ...